Logo image of BIIB

BIOGEN INC (BIIB) Stock Price, Quote, News and Overview

NASDAQ:BIIB - Nasdaq - US09062X1037 - Common Stock - Currency: USD

129.76  +0.32 (+0.25%)

BIIB Quote, Performance and Key Statistics

BIOGEN INC

NASDAQ:BIIB (5/20/2025, 2:58:05 PM)

129.76

+0.32 (+0.25%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High238
52 Week Low110.04
Market Cap19.01B
Shares146.53M
Float145.69M
Yearly DividendN/A
Dividend YieldN/A
PE8.2
Fwd PE8.22
Earnings (Next)07-30 2025-07-30/bmo
IPO09-17 1991-09-17


BIIB short term performance overview.The bars show the price performance of BIIB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10 -15

BIIB long term performance overview.The bars show the price performance of BIIB in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of BIIB is 129.76 USD. In the past month the price increased by 11.12%. In the past year, price decreased by -40.57%.

BIOGEN INC / BIIB Daily stock chart

BIIB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.94 325.97B
AMGN AMGEN INC 13.23 147.71B
GILD GILEAD SCIENCES INC 13.98 134.72B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.31B
REGN REGENERON PHARMACEUTICALS 13.75 65.80B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.63B
ARGX ARGENX SE - ADR 98.33 35.24B
ONC BEIGENE LTD-ADR 5.87 25.42B
BNTX BIONTECH SE-ADR N/A 24.31B
NTRA NATERA INC N/A 20.94B
SMMT SUMMIT THERAPEUTICS INC N/A 17.75B
UTHR UNITED THERAPEUTICS CORP 12.37 13.99B

About BIIB

Company Profile

BIIB logo image Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Company Info

BIOGEN INC

225 Binney Street

Cambridge MASSACHUSETTS 02142 US

CEO: Michel Vounatsos

Employees: 7605

BIIB Company Website

BIIB Investor Relations

Phone: 17814642000

BIOGEN INC / BIIB FAQ

What is the stock price of BIOGEN INC today?

The current stock price of BIIB is 129.76 USD. The price increased by 0.25% in the last trading session.


What is the ticker symbol for BIOGEN INC stock?

The exchange symbol of BIOGEN INC is BIIB and it is listed on the Nasdaq exchange.


On which exchange is BIIB stock listed?

BIIB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BIOGEN INC stock?

43 analysts have analysed BIIB and the average price target is 175.1 USD. This implies a price increase of 34.94% is expected in the next year compared to the current price of 129.76. Check the BIOGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BIOGEN INC worth?

BIOGEN INC (BIIB) has a market capitalization of 19.01B USD. This makes BIIB a Large Cap stock.


How many employees does BIOGEN INC have?

BIOGEN INC (BIIB) currently has 7605 employees.


What are the support and resistance levels for BIOGEN INC (BIIB) stock?

BIOGEN INC (BIIB) has a support level at 115.17 and a resistance level at 129.45. Check the full technical report for a detailed analysis of BIIB support and resistance levels.


Is BIOGEN INC (BIIB) expected to grow?

The Revenue of BIOGEN INC (BIIB) is expected to decline by -3.85% in the next year. Check the estimates tab for more information on the BIIB EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BIOGEN INC (BIIB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BIOGEN INC (BIIB) stock pay dividends?

BIIB does not pay a dividend.


When does BIOGEN INC (BIIB) report earnings?

BIOGEN INC (BIIB) will report earnings on 2025-07-30, before the market open.


What is the Price/Earnings (PE) ratio of BIOGEN INC (BIIB)?

The PE ratio for BIOGEN INC (BIIB) is 8.2. This is based on the reported non-GAAP earnings per share of 15.82 and the current share price of 129.76 USD. Check the full fundamental report for a full analysis of the valuation metrics for BIIB.


What is the Short Interest ratio of BIOGEN INC (BIIB) stock?

The outstanding short interest for BIOGEN INC (BIIB) is 2.19% of its float. Check the ownership tab for more information on the BIIB short interest.


BIIB Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to BIIB. When comparing the yearly performance of all stocks, BIIB is a bad performer in the overall market: 84.18% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BIIB Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to BIIB. BIIB scores excellent on profitability, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BIIB Financial Highlights

Over the last trailing twelve months BIIB reported a non-GAAP Earnings per Share(EPS) of 15.82. The EPS increased by 3.06% compared to the year before.


Industry RankSector Rank
PM (TTM) 15.07%
ROA 5.28%
ROE 8.71%
Debt/Equity 0.27
Chartmill High Growth Momentum
EPS Q2Q%-17.71%
Sales Q2Q%6.13%
EPS 1Y (TTM)3.06%
Revenue 1Y (TTM)1.59%

BIIB Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 73% to BIIB. The Buy consensus is the average rating of analysts ratings from 43 analysts.

For the next year, analysts expect an EPS growth of -7.16% and a revenue growth -3.85% for BIIB


Ownership
Inst Owners94.24%
Ins Owners0.12%
Short Float %2.19%
Short Ratio1.79
Analysts
Analysts72.56
Price Target175.1 (34.94%)
EPS Next Y-7.16%
Revenue Next Year-3.85%